A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Clinical trial NCT06254599 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06254599
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-01
- Primary completion
- 2026-05-01
- Enrollment
- 255
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.